Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 2/20 | 0.32 |
| ▸ | MST1R | Q04912 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9995274 | 0.77 | NOS3 (0.36) | METKDRRETKITPDGFRA | |
| SCHEMBL9995288 | 0.72 | LMNA (0.39) | MET | |
| SCHEMBL12073000 | 0.70 | MET (0.40) | METKDRRETKITPDGFRA | |
| SCHEMBL12071514 | 0.69 | MET (0.36) | METKDRRETKITPDGFRA | |
| SCHEMBL28360056 | 0.66 | MET (0.45) | METKDRRETKITPDGFRA | |
| SCHEMBL15485165 | 0.65 | IMPDH2 (0.34) | MET | |
| SCHEMBL27871830 | 0.64 | MEN1 (0.33) | CYP3A4 | |
| SCHEMBL9995269 | 0.64 | BRAF (0.44) | — | |
| SCHEMBL2552933 | 0.64 | NOS3 (0.47) | METCYP3A4CYP2C9 | |
| SCHEMBL15490440 | 0.64 | MAPT (0.37) | METPDGFRACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358445-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2019-07-23 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| EP-2582700-B1 | RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS | RESPIVERT LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| US-8933228-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| EP-2582700-A2 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | Respivert Limited (GB) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011158044-A2 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | TSLP, CCL11, RORB | MET 4275/4885KDR 4107/4885RET 2195/4885 |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | MET 4275/4885KDR 4107/4885RET 2195/4885 |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | MET 4275/4885KDR 4107/4885RET 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.